ProLynx is a biotechnology company that develops proprietary drug-delivery technologies to extend the half-life of therapeutic molecules.
ProLynx has raised $70.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.
ProLynx's investors include OrbiMed, National Science Foundation, 5AM Ventures, National Institutes of Health, Monograph Capital.
ProLynx is headquartered in San Francisco, United States.
ProLynx is a biotechnology company that develops proprietary drug-delivery technologies to extend the half-life of therapeutic molecules.
ProLynx is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ProLynx — Funding & Investors." VCBacked, December 11, 2025, https://www.vcbacked.co/company/prolynx. Accessed July 19, 2026.
VCBacked. (2025). ProLynx — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/prolynx
{{cite web |title=ProLynx — Funding & Investors |url=https://www.vcbacked.co/company/prolynx |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated